Tuned CAR-T cells – a platform technology

Poor persistence of the T-cell product represents an important challenge with CAR-T cell therapy. This is often due to constitutive activity of the CAR leading to T cells exhaustion before a therapeutic effect can be achieved. To address this challenge, an original...

STEAP1 CAR for metastatic prostate cancer

Business opportunity Scientists at Oslo University Hospital (Norway) have developed a new chimeric antigen receptor (CAR) targeting STEAP1 positive cells. STEAP1 is expressed in about 90% of prostate cancers, and subgroups of other malignancies, and it is an...

CAR T-cell Therapy for Osteosarcoma (OSCAR)

Business opportunity The present technology has the potential to effectively treat children and adults with metastatic osteosarcoma (bone cancer) where the disease has progressed beyond the first and second line treatment. Inven2 seeks collaboration with industrial...